From EZicare™ Self-Sampling to Quantitative 21-Genotype Stratification – Redefining Screening Workflows
As the 2030 timeline approaches, the diagnostic community faces the WHO "90-70-90" challenge: screening 70% of women while managing over 660,000 new cases annually. Laboratories must urgently scale up screening volumes without sacrificing triage precision. Bioperfectus answers this with a seamless "Home-to-Lab" solution.
Expanding Access: EZicare Pad
To reach the unscreened population, the Bioperfectus EZicare Pad bridges the gap between patient privacy and laboratory requirements. Ergonomic design encourages participation among women who refuse traditional exams.
Redefining Triage: Genotyping Meets Quantification
Effective management of "HPV-positive/Cytology-negative" cases demands multidimensional risk stratification. The Bioperfectus HPV Genotyping Real Time PCR Kit empowers labs to go beyond qualitative detection by performing simultaneous 21-genotype differentiation and quantitative viral load analysis:
Comprehensive Profiling: Covers 14 High-Risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and 7 Intermediate/Low Risk types.
Quantitative Insight: Provides viral load data to help clinicians assess infection persistence and disease progression risk, adding a critical layer of precision for triage.
Clinical Confidence: Distinguishes aggressive types, such as 31/33, with a clinical PPA of 91.20% and NPA of 98.20%.
The Workflow: Automated Efficiency
Handle mass screening throughput with the SAW-96 Automated Nucleic Acid Extraction System:
Throughput: Process 96 samples in just 70 minutes.
Walk-Away: Significantly reduces hands-on time and manual errors.
From home sampling to molecular precision, Bioperfectus provides the end-to-end solution needed to accelerate the elimination of cervical cancer.
Ready to upgrade your workflow? Click "Request Information" below to contact Bioperfectus for validation data.
